Role of Vitamin D in Maintaining Renal Epithelial Barrier Function in Uremic Conditions by Mihajlovic, M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/182172
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
 International Journal of 
Molecular Sciences
Article
Role of Vitamin D in Maintaining Renal Epithelial
Barrier Function in Uremic Conditions
Milos Mihajlovic 1 ID , Michele Fedecostante 1 ID , Miriam J. Oost 1, Sonja K. P. Steenhuis 1,
Eef G. W. M. Lentjes 2 ID , Inge Maitimu-Smeele 2, Manoe J. Janssen 1, Luuk B. Hilbrands 3 and
Rosalinde Masereeuw 1,*
1 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
3584 CG Utrecht, The Netherlands; m.mihajlovic@uu.nl (M.M.); m.fedecostante@uu.nl (M.F.);
m.j.oost@students.uu.nl (M.J.O.); s.k.p.steenhuis@students.uu.nl (S.K.P.S.); m.j.janssen1@uu.nl (M.J.J.)
2 Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, 3584 CX Utrecht,
The Netherlands; egwm.lentjes@umcutrecht.nl (E.G.W.M.L.); imaitimu@umcutrecht.nl (I.M.-S.)
3 Department of Nephrology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands;
luuk.hilbrands@radboudumc.nl
* Correspondence: r.masereeuw@uu.nl; Tel.: +31-302-533-529
Received: 29 September 2017; Accepted: 22 November 2017; Published: 26 November 2017
Abstract: As current kidney replacement therapies are not efficient enough for end-stage renal disease
(ESRD) treatment, a bioartificial kidney (BAK) device, based on conditionally immortalized human
proximal tubule epithelial cells (ciPTEC), could represent an attractive solution. The active transport
activity of such a system was recently demonstrated. In addition, endocrine functions of the cells,
such as vitamin D activation, are relevant. The organic anion transporter 1 (OAT-1) overexpressing
ciPTEC line presented 1α-hydroxylase (CYP27B1), 24-hydroxylase (CYP24A1) and vitamin D receptor
(VDR), responsible for vitamin D activation, degradation and function, respectively. The ability to
produce and secrete 1α,25-dihydroxy-vitamin D3, was shown after incubation with the precursor,
25-hydroxy-vitamin D3. The beneficial effect of vitamin D on cell function and behavior in uremic
conditions was studied in the presence of an anionic uremic toxins mixture. Vitamin D could restore
cell viability, and inflammatory and oxidative status, as shown by cell metabolic activity, interleukin-6
(IL-6) levels and reactive oxygen species (ROS) production, respectively. Finally, vitamin D restored
transepithelial barrier function, as evidenced by decreased inulin-FITC leakage in biofunctionalized
hollow fiber membranes (HFM) carrying ciPTEC-OAT1. In conclusion, the protective effects of
vitamin D in uremic conditions and proven ciPTEC-OAT1 endocrine function encourage the use of
these cells for BAK application.
Keywords: bioartificial kidney; conditionally immortalized proximal tubule cells; chronic kidney
disease; end-stage renal disease; vitamin D; uremic toxins; epithelial barrier
1. Introduction
It has been reported that chronic kidney disease (CKD), defined as the sustained presence of
a decreased glomerular filtration rate (GFR) with or without increased albumin excretion, has a
rather high global prevalence, estimated to be between 11% and 13% [1]. The progressive loss
of kidney function will ultimately lead to a permanent state of end-stage renal disease (ESRD).
Kidney failure is accompanied by a noticeable accumulation of a variety of endogenous uremic
metabolites that are not efficiently cleared by the kidneys, leading to a broad range of pathologies,
mostly cardiovascular disease and bone disorders, with reduced quality of life, as well as significantly
increased mortality [2–4]. Although kidney transplantation is the treatment of choice for most patients
with ESRD, patients who are older or have significant comorbidity are not eligible for transplantation.
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Moreover, due to a shortage of donor organs, dialysis therapy is frequently required during the waiting
time for transplantation. However, both hemodialysis and peritoneal dialysis are inefficient techniques
for the removal of waste products, especially larger and protein-bound uremic toxins [5]. Moreover,
hemodialysis decreases the amount of vitamin D in serum [6].
The kidney also has intrinsic endocrine activity, producing hormones and immunomodulatory
molecules. One of the essential hormones is 1α,25-dihydroxy-vitamin D3 (1,25(OH)2D3; calcitriol),
the most active form of vitamin D, which is often deficient in CKD and ESRD populations, giving
rise to severe comorbidities [7,8]. Normally, 25-hydroxy-vitamin D3 (25(OH)D3), mostly bound
to vitamin D binding protein (VDBP), is taken up in proximal tubular epithelial cells (PTEC) by
the multiligand binding receptor megalin (also known as low-density lipoprotein-related protein 2;
LRP2) from the glomerular ultrafiltrate and subsequently converted by 1α-hydroxylase (CYP27B1)
to 1,25(OH)2D3. 1,25(OH)2D3 has both autocrine and endocrine functions [8,9], and by binding to
the intracellular vitamin D receptor (VDR) it is able to control the expression of genes involved in
the regulation of skeletal health, but it can also have a range of other functions with effects on the
cardiovascular and immune systems [10–12]. The activity of 24-hydroxylase (CYP24A1) is responsible
for maintaining vitamin D homeostasis when present in high serum concentrations, as it catalyzes
1,25(OH)2D3 oxidation to inactive metabolites in PTEC that can be excreted in the urine [13,14]. It has
been described that CKD patients have a progressive reduction in 1,25(OH)2D3 serum levels due to
a lower glomerular filtration rate, limited 1α-hydroxylase activity, and lower megalin content [8,15],
but an increase in CYP24A1 levels has also been reported [16]. The vitamin D deficiency in these
patients is directly associated with mineral bone disorders, hyperphosphatemia and cardiovascular
disease, which leads to accelerated disease progression and eventually death [17]. Moreover, vitamin
D deficiency has been associated with epithelial barrier dysfunction and intestinal permeability in
inflammatory bowel diseases (IBD), mostly due to the alteration of gut microbiome composition [18,19].
Because of the shortcomings of current dialysis techniques, novel or improved therapies that can
actively secrete waste molecules and replace essential metabolic kidney functions are being sought
intensively. One of the most promising solutions is a bioartificial kidney device (BAK), composed
of PTEC cultured on hollow fiber membranes (HFM) to mimic proximal tubule physiology [20].
Since the first time BAK was introduced as a possible replacement kidney therapy, many studies have
focused on the development and characterization of such devices [21–25], including human clinical
trials [26], with the main limitations related to the choice of cells that would be safe and efficient
enough, and readily available at the same time. A unique cell type created by our group is represented
by urine-derived conditionally immortalized PTEC (ciPTEC) [27,28] equipped with the organic anion
transporter 1 (OAT1) [29]. This transport protein is responsible for the uptake of many anionic waste
products in kidney proximal tubule, as a first step in their renal excretion. We recently described
the successful culture of ciPTEC-OAT1 on HFM and active transport of uremic toxins as active BAK
component [30–32].
The present study was designed to characterize ciPTEC-OAT1 for the expression of genes
responsible for vitamin D metabolism and function, as well as its activation to the most potent
form, 1,25(OH)2D3. In addition, we evaluated the effect of a specific mixture of eight anionic uremic
toxins (Table 1), mimicking uremic conditions of CKD and ESRD, on vitamin D activation and function.
In particular, we focused on the beneficial effects of vitamin D on cell viability, oxidative stress,
inflammation and epithelial monolayer barrier function of ciPTEC-OAT1 cultured on biofunctionalized
polyethersulfone HFM. The ability of ciPTEC-OAT1 to produce vitamin D, exerting protective effects
on cells, could greatly improve both BAK function and application as a treatment modality.
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Table 1. Concentrations of anionic uremic toxins in healthy individuals, uremic patients, and as
applied in the present study. Concentrations used are adapted from EUToX Uremic Solutes Database
(http://uremic-toxins.org/DataBase.html) and Jansen et al. [33].
Compound Normal conc. (µM)(Mean ± SD)
Uremic conc. (µM)
(Mean ± SD) 1× UT mix (µM) Structure
Indoxyl sulfate 2.3 ± 18.8 173.5 ± 121.9 100
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reduction in 1α-hydroxylase expression was observed after 1,25(OH)2D3 treatment when used at 1 µM,
and a more than 1000-fold increase in CYP24A1 expression, regardless of the vitamin D concentration
used (Figure 1b). No significant changes in gene expression were observed in the presence of a uremic
toxins mixture (UT mix) at 1× or 2.5× concentrations (Figure 1c), which was used to mimic the
conditions of kidney patients.
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2.2. Conversion of 25(OH)D3 to 1,25(OH)2D3 by ciPTEC-OAT1
To assess whether ciPTEC-OAT1 are able to produce the most active form of vitamin D,
1,25(OH)2D3, cells were exposed to 100 nM 25(OH)D3 for 24 h, in the presence or absence of
1α-hydroxylase inhibitor—ketoconazole (10 µM). Measured levels of 1,25(OH)2D3 confirmed that
ciPTEC-OAT1 did produce the active form of vitamin D and the conversion was sensitive to inhibition
by ketoconazole (Figure 2a). Uremic conditions (1× UT mix) did not influence the vitamin D activation
(Figure 2b).
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Figure 2. Conversion of vitamin D precursor to biologically active 1,25(OH)2D3 by ciPTEC-OAT1.
(a) Release of 1,25(OH)2D3 in cell culture supernatant after 24 h incubation with inactive 25(OH)D3
(100 nM), in absence or presence of 1 α-hydroxylase inhibitor, ketoconazole (KC; 10 µM); (b) Release of
1,25(OH)2D3 after 24 h incubation with 25(OH)D3 (100 nM), in absence or presence of ketoconazole
(10 µM) and 1× UT mix. Concentration expressed as pmol/L (mean ± SEM). Three independent
experiments were performed. ** p < 0.01 (One-way ANOVA followed by Dunnett’s multiple comparison
test, using as a control either untreated sample or 25(OH)D3 treated sample, as indicated).
2.3. Protective Effect of 1,25(OH)2D3 on Anionic Uremic Toxin Mix Induced Cell Toxicity
To further examine the effect of 1,25(OH)2D3 on ciPTEC-OAT1 viability in normal and uremic
conditions, cells were exposed to several concentrations of 1,25(OH)2D3 in the absence or presence
of increasing concentrations of UT mix. As shown in Figure 3a, the active form of vitamin D alone
did not compromise cell viability. However, anionic uremic toxins did reduce cell viability after
24 h incubation, by approximately 10%, 25%, and 62% for 2.5×, 5×, and 10× concentrated mixtures,
respectively (Figure 3b). Co-incubation of 1,25(OH)2D3 with UT mix could mitigate the decrease in
cell viability, especially when toxicity was induced by higher concentrations of UT mix (5× and 10×;
Figure 3c).
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Figure 3. Effect of vitamin D on ciPTEC-OAT1 viability in uremic conditions. CiPTEC-OAT1 viability
(relative to untreated cells) following 24 h exposure to (a) 1,25(OH)2D3 alone (100 nM, 500 nM and
1 µM), (b) increasing concentrations of UT ix ( , 2.5 , 5×, and 10×), and (c) combination of
1,25( )2D3 and UT ix at ll ti t ti . Four independent experi ents ere
perfor ed in plicate. * p < 0.05, * p < 0.01, * p 0.001 ( ne- ay OV , ett’s ltiple
co parison test).
2.4. Protective Effect of 1,25(OH)2D3 on Anionic Uremic Toxin ix Induced Oxidative Stress
To evaluate ciPTEC- T1 susceptibility to oxidative stress in ure ic conditions and the
anti-oxidative effect of 1,25( )2D3, intracellular reactive oxygen species (R S) generation as
easured. Cells were exposed to 5× UT mix, 1,25(OH)2D3 (500 nM or 1 µM) or a combination of
UT mix and 1,25(OH)2D3 for 2 h. UT mix induced a 1.5-fold increase in ROS production, which
was attenuated significantly when adding vitamin D as a co-treatment, regardless of concentration
(Figure 4). Also, the positive control H2O2 (200 µ ) significantly enhanced ROS generation (Figure 4).
Using 10× UT mix, similar effects of vitamin D on intracellular ROS levels were observed (Figure S3a).
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Figure 4. Vitamin D effect on intracellular ROS production in ciPTEC-OAT1. Relative ROS production
in ciPTEC-OAT1 after 2 h exposure to 1,25(OH)2D3 (500 nM and 1 µM), 5× UT mix, combination of the
two at previous concentrations and H2O2 (100 µM and 200 µM). Three independent experiments were
performed in duplicat . * p < 0.05, ** p < 0.01, *** < 0.001 (One-way ANOVA followed by Dunnett’s
multiple c mparison test, using as a control either untr ated sample or 5× UT mix, as indicated).
2.5. Anti-Inflammatory Effect of 1,25(OH)2D3 in Inflammatory and Uremic Conditions in ciPTEC-OAT1
Interleukin-6 (IL-6) levels in cell culture supernatant were measured to assess the effect of UT mix
and vitamin D on the inflammatory response of ciPTEC-OAT1. Lipopolysaccharide (LPS) (10 µg/mL),
which was used as a positive control, induced a 3-fold increase in IL-6 levels after 24 h exposure.
Vitamin D, however, was able to reverse this pro-inflammatory effect of LPS by reducing the IL-6
levels. A 1.6-fold reduction was found for 100 nM and 500 nM, and a 1.8-fold reduction for 1 µM
of 1,25(OH)2D3 (Figure 5a). A 2-fold and 2.8-fold increase in IL-6 levels was observed following the
exposure to 1× and 2.5× UT mix, respectively. Similar to what was observed for LPS, a small but
evident trend in IL-6 level reduction was detected after co-treatment with 1,25(OH)2D3 (Figure 5b,c).
In all conditions, TNF-α levels measured were below the limit of detection.
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IV coated HFM, as described previously [30,32]. Tight monolayer was confirmed by the presenc
Int. J. Mol. Sci. 2017, 18, 2531 9 of 18
of zonula occludens 1 (ZO-1) tight junction protein and actin staining (Figure 6a). Figure 6b shows
inulin-FITC diffusion through HFM containing matured monolayers of ciPTEC-OAT1, untreated,
exposed to 1 µM of 1,25(OH)2D3, 2.5× UT mix or the combination of the two treatments for 24 h.
UT mix increased inulin-FITC leakage to 813 ± 136 nmol·min−1·cm−2 compared to the untreated
fibers (400 ± 78 nmol·min−1·cm−2; p < 0.01). Simultaneous exposure to 1,25(OH)2D3 could partially
prevent the increase in inulin-FITC leakage induced by UT mix 2.5× (to 655 ± 85 nmol·min−1·cm−2).
Figure 6c depicts a schematic presentation of inulin-FITC leakage in HFM carrying ciPTEC-OAT1 in
examined conditions.
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Figure 6. Transepithelial barrier function of ciPTEC-OAT1 cultured on hollow fiber membranes (HFM)
in uremic conditions. (a) ciPTEC-OAT1 monolayer formation on L-DOPA (2 mg/mL) and collagen IV
(25 µg/mL) coated HFM; ZO-1 expression (red), actin filaments (green) and nuclear staining with DAPI
(blue) (25× magnification); (b) transepithelial inulin-FITC diffusion in fibers containing untreated
cells, cells exposed to 1,25(OH)2D3 (1 µM), 2.5× UT mix and their combination for 24 h. Diffusion
is expressed as nmol·min−1·cm−2 (mean ± SEM). Two independent experiments were performed in
triplicate. ** p < 0.01 (One-way ANOVA, Dunnett’s multiple comparison test); (c) schematic presentation
of inulin-FITC diffusion across HFM containing ciPTEC-OAT1 after various treatments.
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3. Discussion
In the present study, we demonstrated the ability of ciPTEC-OAT1 to produce the most active
form of vitamin D, 1,25(OH)2D3, and its beneficial effect on various aspects of uremic conditions
in ciPTEC-OAT1, including the protective effect on epithelial monolayer tightness. Considering
the importance of the vitamin D deficiency often observed in CKD and ESRD, and the fact that
vitamin D production is one of the main endocrine functions of proximal tubule cells, we were
interested in determining whether ciPTEC-OAT1, intended for BAK purposes, possess all the necessary
enzymes responsible for vitamin D metabolism. It has been shown that proximal tubule cells express
1α-hydroxylase, which is responsible for 25(OH)D3 conversion into 1,25(OH)2D3, as well as CYP24A1,
involved in 1,25(OH)2D3 degradation [34]. Besides the proximal tubule, there are other, extra-renal
sites expressing these enzymes and producing vitamin D ,such as the cells of the immune system
(macrophages, monocytes, dendritic cells), and epithelial cells of the gastrointestinal tract, skin, breast,
and lungs [35–41]. However, the major part of circulating vitamin D levels is kidney-derived, hence the
severe deficiency is due to kidney failure [8]. We first evaluated the baseline expression of the genes for
the activating and degrading enzymes and found that both are present in ciPTEC-OAT1, with a higher
basal expression of the activating enzyme compared to the inactivating one. In line with the literature,
following exposure to the active form of vitamin D, we observed a significant downregulation of
1α-hydroxylase and substantial upregulation of CYP24A1, confirming the existence of the negative
feedback of 1,25(OH)2D3 on its circulating concentration [42,43]. Moreover, VDR is also expressed
but not influenced by vitamin D treatment. Neither normal (1×) nor high (2.5×) concentrations of
uremic toxins affected the expression of the enzymes and VDR, indicating that gene expression is not
likely be altered in uremic conditions. In addition, we determined the actual conversion of 25(OH)D3
into 1,25(OH)2D3 in basic and uremic conditions. Cells were treated with a physiologic concentration
of inactive vitamin D (100 nM, corresponding to 40 ng/mL in healthy individuals) and after 24 h
the amount of active form of vitamin D generated was 32.5 pmol/L, corresponding to 13.5 pg/mL,
which is slightly below the range of the active vitamin D serum levels in healthy patients [44,45].
Although speculative, this indicates that ciPTEC-OAT1 may be able to sufficiently produce the active
form of vitamin D. In accordance with gene expression levels in uremic conditions, we found that the
conversion of 25(OH)D3 was not affected by uremic toxins, suggesting a normal endocrine function of
ciPTEC-OAT1 in conditions relevant to BAK applications and kidney disease.
In addition to its well-described roles, such as maintenance of calcium homeostasis and
mineralization, vitamin D is able to exert other, non-calciotropic effects [46]. Among the most relevant
ones are certainly immunomodulatory actions [47,48], with promotion of innate immune responses
and the ability of immune system to fight infections [49–51], but also the suppression of the adaptive
immune system with generation of tolerance, as shown for various auto-immune disorders (multiple
sclerosis, type 1 diabetes, systemic lupus erythematosus and rheumatoid arthritis) [52–55]. Moreover,
vitamin D is also involved in modulation of cell growth and proliferation, both in benign hyperplastic
conditions and various cancer types [56].
In this study, we were particularly interested in the autocrine actions of vitamin D and therefore
evaluated its effects on several cellular aspects of renal PTEC in uremic conditions. Initially, we
observed that uremic toxins affect cell viability in a dose-dependent manner, while vitamin D did
not have any effect. However, in the presence of anionic uremic toxins, especially at higher doses,
vitamin D could restore cell viability. Numerous studies have described that some uremic toxins,
such as indoxyl sulfate (IS), p-cresyl sulfate (pCS), and indole-3-acetic acid (IAA), are associated with
increased inflammatory responses and oxidative stress both in vitro and in vivo [57–66]. To further
address this, we measured IL-6 release by cells as an indication of inflammatory response, and ROS
production, as a marker of oxidative stress, in uremic conditions and in the presence or absence of
1,25(OH)2D3 in ciPTEC-OAT1. We found that uremic toxins do increase IL-6 secreted levels, as well as
ROS intracellular generation. Moreover, our results indicate that 1,25(OH)2D3 is able to reduce this
increase in IL-6 levels and ROS production, confirming that vitamin D indeed has protective effects
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in uremic conditions, as suggested previously by in vivo studies, evaluating therapeutic effects of
paricalcitol, a VDR activator, in uremic rats and hemodialysis patients [67–69].
A growing body of evidence suggests that vitamin D is essential for the correct functioning and
maintenance of epithelial barriers, including gut mucosal barrier, corneal, pulmonary and kidney
epithelial barriers, and its deficiency has been reported to promote barrier dysfunction and increased
permeability [18,70–72]. The key tight junction proteins responsible for a tight monolayer formation
in kidney proximal tubule are claudin 2 and ZO-1 [73,74]. We determined the effect of vitamin D
on the stability of the proximal tubule epithelial monolayer in uremic conditions. For that purpose,
ciPTEC-OAT1 were cultured on double-coated HFM to create kidney tubules consisting of mature
epithelial cell monolayers, expressing both ZO-1 and claudin 2 (Figure S4a). Interestingly, we observed
increased barrier permeability in the presence of uremic toxins, as shown by inulin-FITC leakage.
However, in the presence of vitamin D, a clear trend towards a smaller increase in inulin-FITC diffusion
was detected, suggesting the protective effect of vitamin D on the proximal tubule epithelial barrier
integrity. Because the gene expression levels of ZO-1 and claudin 2 were not significantly influenced
by uremic toxins or by vitamin D (Figure S4b,c), we expect that the effect of vitamin D in attenuating
epithelial barrier permeability might be due to a redistribution of tight junction proteins rather than an
increased protein expression, as observed previously for the intestinal barrier [18].
The findings of the present study clearly support further development of BAK as a treatment
modality in patients with ESRD. Extensive previous studies described an efficient way of culturing
ciPTEC-OAT1 on double-coated HFM with the formation of tight epithelial monolayers, as well as the
active transport activity of both OAT1 and OCT2, proteins responsible for the clearance of uremic waste
metabolites [30,32]. In addition, the lack of ciPTEC induced alloimmune response in vitro [75] and
the successful upscaling of the BAK device [76] further encourage the use of these cells. Our current
demonstration of the ability of the cells to activate and secrete the most active form of vitamin D
is an additional important asset of the system. However, future studies should further investigate
the choice of membranes used to support cell attachment, growth and monolayer formation, as this
could potentially abolish the vitamin D activation function of ciPTEC-OAT1. It has been shown that
some membrane types, in particular highly adsorptive and high cut-off membranes, could lead to a
significant reduction in VDBP and 25(OH)D3 levels [6], potentially compromising the availability of
25(OH)D3 for megalin uptake and conversion by 1α-hydroxylase. For that reason, the polyethersulfone
membranes used to support ciPTEC-OAT1 in the current settings should be tested for its suitability for
use in BAK devices.
In conclusion, the ability of ciPTEC-OAT1 to produce active vitamin D could considerably boost
BAK function, thus allowing the improvement of health status of kidney patients, not only by removing
the excessive amounts of protein bound uremic toxins, but also by replicating one of the key endocrine
functions of the proximal tubule. Eventually, the presence of 1,25(OH)2D3 would greatly contribute
to the maintenance of a strong epithelial monolayers for correct and efficient BAK function, and to
improved mineral homeostasis and skeletal and cardiovascular health in CKD and ESRD patients.
Future experiments will be designed to evaluate the safety and efficacy of a prototype BAK device
in vivo, including the assessment of the beneficial effects of vitamin D as presented in this study.
4. Materials and Methods
4.1. Reagents
All reagents (including all but two of the uremic toxins) were obtained from Sigma-Aldrich
(Zwijndrecht, The Netherlands) unless stated otherwise. The uremic toxins p-cresyl sulfate (pCS) and
p-cresyl glucuronide (pCG) were synthesized by the Institute for Molecules and Materials, Radboud
University, Nijmegen, The Netherlands, as described [32]. Ketoconazole, 1α,25-dihydroxy-vitamin
D3 (1,25(OH)2D3) and 25-hydroxy-vitamin D3 (25(OH)D3) were purchased form Enzo Life Sciences
(Raamsdonksveer, The Netherlands). MicroPES type TF10 hollow fiber capillary membranes (wall
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thickness 100 µm, inner diameter 300 µm, max pore size 0.5 µm) were purchased from Membrana
GmbH (Wuppertal, Germany). Cell culture plates were obtained from Greiner Bio-One (Monroe,
NC, USA).
4.2. Cell Culture of ciPTEC-OAT1
The ciPTEC-OAT1 cell line was cultured as reported previously [29]. Briefly, cells were
cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (1:1 DMEM/F-12) (Gibco,
Life Technologies, Paisley, UK) supplemented with 10% fetal calf serum (FCS) (Greiner Bio-One,
Alphen aan den Rijn, The Netherlands), 5 µg/mL insulin, 5 µg/mL transferrin, 5 µg/mL selenium,
35 ng/mL hydrocortisone, 10 ng/mL epidermal growth factor and 40 pg/mL tri-iodothyronine to
form a complete culture medium, without addition of antibiotics and up to a maximum of 60 passages.
Cells were cultured at 33 ◦C and 5% (v/v) CO2 to allow proliferation and prior to the experiments
seeded at a density of 55,000 cell/cm2. Subsequently, cells were grown for one day at 33 ◦C, 5% (v/v)
CO2 to allow adhesion, then cultured for seven days at 37 ◦C, 5% (v/v) CO2 for differentiation and
maturation, refreshing the medium every other day.
4.3. ciPTEC-OAT1 Exposure to Uremic Toxins Mixture
In order to replicate the uremic conditions present in kidney patients, a specific mixture of
eight known anionic uremic toxins (Table 1), predominantly derived from endogenous metabolism
pathways and food digestion in the gut [33], and corresponding approximately to the concentrations
found in patients (1×), or higher (2.5×, 5× and 10×) (Table 1), was used in the present study. It was
prepared as a 100× concentrated mixture in a serum-free medium and subsequently diluted to
desired concentrations.
4.4. Cell Viability Assay
Cell viability was measured using PrestoBlue® cell viability reagent (Life Technologies). After
seven days of maturation, cells were exposed to increasing concentrations of 1,25(OH)2D3 (100 nM,
500 nM, 1 µM), anionic UT mix (1-, 2.5-, 5-, or 10-times concentrated) and a combination of 1,25(OH)2D3
and UT mix in the previously mentioned concentrations. Following 24 h incubation at 37 ◦C, 5% (v/v)
CO2, ciPTEC were rinsed once with Hank’s Balanced Salt Solution (HBSS; Gibco, Life Technologies)
and incubated with PrestoBlue® cell viability reagent (diluted 1:10 in complete culture medium), in the
dark. After 1 h incubation at 37 ◦C, 5% (v/v) CO2, the fluorescence was measured using the Fluoroskan
Ascent FL microplate reader, at excitation wavelength of 530 nm and emission wavelength of 590 nm.
Data were corrected for the background, normalized to untreated cells, and presented as relative
cell viability.
4.5. RNA Extraction, cDNA Synthesis, and Real-Time PCR
Total RNA from ciPTEC-OAT1 exposed to 1,25(OH)2D3 (100 nM and 1 µM) and UT mix (1× and
2.5×) for 24 h, was isolated using the RNeasy Mini kit (Qiagen, Venlo, The Netherlands) according to
the manufacturer’s instructions and quantified using the NanoDrop® ND-1000 spectrophotometer.
Reverse transcription of RNA to complementary DNA (cDNA) was performed using the iScriptTM
Reverse Transcription Supermix (Bio-Rad Laboratories, Hercules, CA, USA) following manufacturer’s
instructions. Subsequently, Real-Time PCR was performed using the iQ SYBR® Green Supermix
(Bio-Rad Laboratories) as indicated in manufacturer’s protocol and by means of CFX96TM Real-Time
PCR Detection System (Bio-Rad Laboratories). The data were analyzed using Bio-Rad CFX ManagerTM
Software version 3.1 (Bio-Rad Laboratories) and expressed as relative gene expression, using
untreated cells as the reference sample. HPRT1 was used as a housekeeping gene for normalization.
Specific sense and anti-sense primers for HPRT1 (forward: ACATCTGGAGTCCTATTGACATCG;
reverse: CCGCCCAAAGGGAACTGATAG), VDR (forward: CTGACCCTGGAGACTTTGAC; reverse:
TTCCTCTGCACTTCCTCATC), 1α-hydroxylase, (forward: GGCAGAGTCTGAATTGCAAAT; reverse:
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CCGGGTCTTGGGTCTAACTG), CYP24A1 (forward: GGCCTCTTTCATCACAGAGCT; reverse:
GCCTATCGCGACTACCGCAA), ZO-1 (forward: ATGGTGTCCTACCTAATTCAACTCAT; reverse:
GCCAGCTACAAATATTCCAACATCA) and claudin 2 (forward: ACCTGCTACCGCCACTCTGT;
reverse: CTCCCTGGCCTGCATTATCTC) were synthesized by Biolegio (Nijmegen, The Netherlands).
4.6. Agarose Gel Electrophoresis
Real-time PCR products of the VDR, 1α-hydroxylase and CYP24A1 genes were detected by
agarose gel electrophoresis. An 1.5% agarose gel was prepared in Tris-Borate-EDTA (TBE) buffer,
including the SYBRTM Safe DNA gel stain (1:10,000) (Invitrogen, Carlsbad, CA, USA) for visualization
of cDNA fragments. Loading buffer (30% glycerol, 0.25% bromophenol blue) was added 1:6 to the
PCR product samples prior to loading them in the agarose gel. The 100 bp DNA ladder (Invitrogen,
Carlsbad, CA, USA) was used to determine the size of the fragments. Electrophoresis was conducted
at 24 W and 100 V using Bio-Rad PowerPacTM HC power supply (Bio-Rad Laboratories, Hercules,
CA, USA). Following electrophoresis, the fragments were visualized using ChemiDocTM MP Imaging
System (Bio-Rad Laboratories) and data analyzed by means of Image Lab software (version 5.2,
Bio-Rad Laboratories).
4.7. Quantification of 1α,25-Dihydroxy-Vitamin D3
Matured ciPTEC-OAT1 were exposed to 25(OH)D3 100 nM, ketoconazole 10 µM and the
co-treatment, as well as 1× UT mix alone and in the presence of 25(OH)D3 100 nM, ketoconazole 10 µM
or both of them. Ketoconazole was always added 2 h prior to the treatment with 25(OH)D3 and UT
mix. After 24 h incubation, cell culture supernatants were collected, centrifuged for 10 min at 240× g,
4 ◦C, and stored at −80 ◦C. 1,25(OH)2D3 was quantified after immuno-extraction using a competitive
RIA (IDS AA-54F1; IDS Immunodiagnostic Systems GmbH, Frankfurt am Main, Germany).
4.8. Enzyme-Linked Immunosorbent Assay (ELISA)
The production of IL-6 and TNF-αwas measured using the Enzyme-Linked Immunosorbent Assay
(ELISA). Cell culture supernatants were collected after 24-h treatments with 1,25(OH)2D3 (100 nM,
500 nM, 1 µM), UT mix (1 and 2.5×), a combination of 1,25(OH)2D3 and UT mix in the previously
mentioned concentrations, as well as LPS (Escherichia coli 0127:B8) 10 µg/mL alone or as a co-treatment
with increasing concentrations of 1,25(OH)2D3. Afterwards, cell culture supernatants were centrifuged
for 10 min, 240× g, 4 ◦C, and stored at−20 ◦C. DuoSet® ELISA Development Systems kits (IL-6 #DY206,
TNF-α #DY210; R&D Systems, Abingdon, UK) were used to quantify the cytokines levels in complete
cell culture medium supernatants following manufacturer’s instructions. The optical density was
determined using the iMark Microplate Absorbance Reader (Bio-Rad Laboratories, Hercules, CA,
USA) set to 450 nm. Each sample was measured in duplicates and quantification was done using
Microplate Manager software (version 6.0, Bio-Rad Laboratories), generating a four parameter logistic
(4-PL) curve-fit.
4.9. Intracellular Reactive Oxygen Species (ROS) Detection
Intracellular ROS generation was measured by means of cell permeant fluorogenic substrate
2′,7′-dichlorofluorescein diacetate (H2DCFDA). Briefly, cells were washed once with HBSS,
immediately loaded with H2DCFDA (50 µM in serum-free medium) and incubated at 37 ◦C, 5%
(v/v) CO2, in the dark for 45 min. Afterwards, cells were washed with a complete culture medium and
exposed to various concentrations of 1,25(OH)2D3 (500 nM and 1 µM) and 5× UT mix for 2 h at 37 ◦C,
5% (v/v) CO2, in the dark. H2O2 (100 µM and 200 µM) was used as a positive control. Following
the incubation, cells were washed twice with HBSS and lysed using 0.1 M NaOH for 10 min. Finally,
fluorescence was measured at an excitation wavelength of 492 nm and emission wavelength of 518 nm,
using a fluorescent microplate reader (Fluoroskan Ascent FL, Thermo Fisher Scientific, Vantaa, Finland).
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Measured fluorescence values were corrected for the fluorescence of the blank sample (non-stained
lysed cells) and used to calculate relative ROS production, using untreated cells as the reference.
4.10. CiPTEC-OAT1 Epithelial Monolayer Integrity
To investigate the effect of vitamin D on epithelial monolayer barrier function in uremic conditions,
ciPTEC-OAT1 were cultured on L-DOPA (2 mg/mL) and collagen IV (25 µg/mL) coated HFM,
mounted on a tailor-made flow chamber as described previously [30,32]. HFM with untreated mature
ciPTEC-OAT1 monolayers and those exposed to 1,25(OH)2D3 (1 µM), 2.5× UT mix or a combination
of both, were perfused with inulin-FITC (0.1 mg/mL) in Krebs–Henseleit buffer supplemented with
10 mM HEPES, pH 7.4, for 10 min. Next, aliquots from the apical compartment were collected and used
to measure fluorescence by means of fluorescent microplate reader (Fluoroskan Ascent FL, Labsystems),
at excitation wavelength of 492 nm and emission wavelength of 518 nm. Background values were
subtracted and normalized arbitrary fluorescence unit (AFU) data were converted and plotted as
nmol·min−1·cm−2, as described previously [32]. From each single replicate (fiber), three different
regions, with an area of 0.157 cm2, were analyzed.
4.11. Immunocytochemistry
To assess the expression of tight junction protein ZO-1, ciPTEC-OAT1 cultured on double-coated
HFM were fixed with 4% (w/v) paraformaldehyde dissolved in PHEM buffer (120 mM PIPES, 50 mM
HEPES, 4 mM MgCl2, 20 mM EGTA) for 15 min. After washing the samples with HBSS, block solution
(2% (v/v) FCS, 2% (w/v) bovine serum albumin (BSA), 0.1% (v/v) Tween20 in HBSS) was added.
The primary antibody, rabbit anti-human ZO-1 (Invitrogen, Carlsbad, CA, USA), was diluted in
blocking buffer (1:200) and incubated overnight at 4 ◦C. Following three washing steps with HBSS,
the secondary antibody, goat anti-rabbit IgG Alexa 568 (Life Technologies, Eugene, OR, USA) was
added in a concentration of 1:200 and incubated for 1 h at room temperature. Finally, ProLongTM
Gold antifade reagent containing DAPI (Life Technologies, Eugene, OR, USA) was used for nuclear
staining, and to mount the fibers containing cells on the Willco glass bottom dishes (WillCo Wells B.V.,
Amsterdam, The Netherlands). Cells were imaged using confocal microscope (Leica TCS SP8 X, Leica
Microsystems CMS GmbH, Wetzlar, Germany) and analyzed using Leica Application Suite X software
(Leica Microsystems CMS GmbH).
4.12. Data Analysis
All data are presented as mean ± standard error of the mean (SEM). Statistical analysis was
performed using one-way ANOVA followed by Dunnett’s multiple comparison test. A p-value < 0.05
was considered significant. Datasets were assessed for normality and equal variances assumptions
prior to one-way ANOVA, using Kolmogorov–Smirnov and Bartlett’s tests, respectively. Even though
some datasets did not meet one of the assumptions, due to a limited number of measurements, the
expected effect on the Type I error in one-way ANOVA is minimal. Software used for statistical analysis
was GraphPad Prism (version 6.07; GraphPad software, La Jolla, CA, USA). In most experiments at
least three independent experiments were performed in duplicates, unless otherwise stated. The exact
sample size for each experiment is indicated in the corresponding figure legend.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2531/s1.
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